Member Info for Brighty1

Yes, no doubt about it that the 1400% gain at CHAR could be replicated here. Some might recall that last year EnQuest agreed to pay an initial USD325 million to acquire a %age stake in Suncor Energy's 27% stake in the Golden Eagle area, which included the Golden Eagle, Peregrine and Solitaire fields, "with additional contingent consideration of up to USD50 million". The Suncor/Enquest deal is a cracking example of a potential %age farm in/out of BOIL's Dunrobin and Golspie prospects, especially now that M&A activity is increasing again in the north sea arena. With BOIL holding a 15% working interest in licence P2478, could a deal for a JV/Farm in/out for P2478 finally be close? This would certainly put a rocket booster in the BOIL share price if a deal for Dunrobin. A CHAR x 14 gain would then be more than likely. Good luck, Brighty

A lot of smoke and mirrors activity going on with briefing and counter briefings including that Guardian article. It would certainly help if ABDX rebutted the incorrect narrative as it is worth noting Point 35, pasted below, from the 77 point rebuttal from ABDX dated 4.5.21. It clearly states:

"For clarity, the CE marking for professional use adhered to MHRA’s target product profile which
required 200 confirmed positive and 200 confirmed negative samples. Abingdon’s CE marking
data included (along with other data on, for example, product performance, product stability,
manufacturing reproducibility, lack cross-reactivity to antibodies to other viruses, quality control
procedures and standard operating procedures), analysis of 350 negative samples and 203
positive samples performed during an independent assessment at Ulster University, plus an
additional 100 pre-pandemic negative samples analysed at Abingdon’s laboratories in York. This
gave a specificity of 99.6% (95% confidence interval 98.4 to 99.95%) and sensitivity of 98.03%
(95% confidence interval 95.0 to 99.5). The Ulster University data set has since been expanded
to include 304 positive and 350 negative samples with a sensitivity of 97.7% and specificity of
100%.48

46 An additional point regarding NP is that it is more conserved across the coronavirus family than spike protein.
This produces the potential of cross-reactivity with other coronaviruses and false positive results.
47
https://www.abingdonhealth.com/app/uploads/2021/01/AH-ISO13485-EXP-20211209.pdf
48
https://www.medrxiv.org/content/10.1101/2020.09.29.20201509v1;
https://www.medrxiv.org/content/10.1101/2020.09.29.20201509v2.full.pdf+html

Good luck, Brighty

Yes very encouraging and hot on the heels of Perrone Robotics & Guident signing their strategic alliance 2 weeks ago to accelerate the roll-out of land-based delivery drones. This is more value enhancing news from Guident ahead of TEK's results due any day now. Don't forget too that the autonomous vehicle market is expected to reach $556 billion by 2026. Right place. Right time etc. Short term our portfolio of Lucyd, Salarius and Bell will help push the TEK share price higher but longer term Guident is the jewel in the TEK crown. Good luck, Brighty

JJ, I hope this helps. The source is from the RNS titled:

* "Disclosure of Detailed Grounds for Resistance - Clarification regarding factual inaccuracies in relation to the judicial review proceedings" dated 9th August 2021 from ABDX.

* In the disclosure it states in black and white that "The Company was told by DHSC in January 2021, both verbally and in writing, that payment for the 1 million tests had been cleared for payment".

* There's also a very interesting letter from ABDX's solicitors, Bristows, that investors should read for reassurance, dated 4th May. I have pasted the link to this 16 page letter below. It contains 77 points re the case and it is well worth digesting.

https://www.abingdonhealth.com/app/uploads/2021/08/2021.05.04-Letter-to-Rook-Irwin-Sweeney-LLP-V5.pdf

Good luck, Brighty

Here is a breakdown of the numbers from the 9th August ABDX disclosure briefing and a reminder from our CEO of why this week could be the tipping point for our share price once this court case is resolved:

The following information is sourced from the 9th August 2021 disclosure filed by ABDX.

* ABDX is owed in total £8.9m from the DHSC

* For a combination of tests delivered (£5.2m)

* Components bought on behalf of DHSC (£3.3m)

* Plus a further commitment of (£0.4m) for goods not yet delivered to which DHSC retain legal title

* The Group believes that there are no legal grounds as to why these monies are not being paid in full

* The Company can confirm that no member of the senior management has sent or received texts or WhatsApp messages with Lord Bethell or any other Government ministers

* The mobile phones of the senior management team at Abingdon Health have not been replaced or lost and the senior management team are happy to confirm in sworn evidence that no such text or WhatsApp messages were sent or received

* Abingdon is participating as an ‘interested party’ in the judicial review to ensure that accurate information is available during the process

* The Company was told by DHSC in January 2021, both verbally and in writing, that payment for the 1 million tests had been cleared for payment.

* As a British company and a leader in the field of lateral flow testing, Abingdon Health responded to the Government’s request for healthcare industry experts to pull together in a national and international emergency, and this led to the formation of the UK-RTC, a consortium of UK diagnostic companies

AND don't forget that once the case has been settled what ABDX has to offer....

“We believe that antibody testing programmes will be rolled-out around the world, where there are clear use cases for antibody testing, including checking levels of immunity both prior to and after vaccinations, as well as potentially assess which individuals should be prioritized in vaccination or vaccine booster programmes. Given that our AbC-19™ rapid test could be a key tool in maintaining public safety, confidence in vaccines and supporting effective vaccine booster campaigns, it is very disappointing that we have been caught in the cross-fire of a battle over transparency and accountability, which has meant this British developed and British made rapid diagnostic has not been substantially deployed here in the UK" - CEO, Abingdon. 9th August 2021

Good luck, Brighty

"Airspan Networks and Guident Testing Autonomous Vehicles with Remote Monitoring". Good luck, Brighty

I totally agree. If ABDX can produce the volumes outlined in its 1st December funding announcement then £1+ during this year is a very real possibility. 20p should be achieved pretty soon and in the next quarter we should see a share price of 48p - 55p on the back of the £8.45 million being paid by the DHSC & more contract news. Good luck, Brighty

"Record Results for the Full Year" is what I'm expecting to be announced. Cliff Gross was very bullish at the 6 month point and when you factor in the below it is likely that our final results RNS will be sensational:

Belluscura® Plc: IPO Price of 45 pence (8.6 million GBP / US$10.8m) now valued at 108p a share today. i.e. Tek's investment in BELL has more than doubled in the period plus Lucyd® and Salarius® have both had a superb last 12 months and there's encouraging news from Guident expected too.

Here's to 50p a share soon.

Good luck, Brighty

Excellent numbers from Lloy today:

* "Underlying profit up 26 per cent to £2.0 billion in the quarter, driven by strong net income growth"

And as a result Lloy is enhancing its guidance for 2022...

* " Given the solid financial performance in the first quarter of 2022 and based on current business performance expectations and macroeconomic assumptions, the Group is enhancing its guidance for 2022"

My favourite UK banking juggernaut is starting to deliver impressive numbers again.....

Good luck, Brighty

The Permanent Secretary of the DHSC is Sir Chris Wormald and investors should make contact with him and complain. You can contact him at Permanent.secretary@dhsc.gov.uk
Also worth contacting Dr Jenny Harries CEO UKHSA at CEX.UKHSA@dhsc.gov.uk
Plus, the Chair of Public Accounts Committee Rt Hon Meg Hillier MP pubaccom@parliament
Good luck, Brighty

Sorry but I can't believe that people on here are excited about our share price moving up a few percent to 76p!! We were 40p+ higher just a couple of months ago before the new strategy was announced and on 8th Jan 2018 when the current CEO arrived we were at 168p approx. This is a shocking share price performance. SP Expectations are being managed lower by our BOD. What exactly has our current ceo achieved for shareholders at ITV since she arrived? I can't think of one positive. The share price is down significantly because the market just does not believe in the ITV strategy and our ceo. Good luck, Brighty

I agree Faceface. An investment is an increase in value over a period of time not a few days. I'm here for £2+ and I really think that will be achieved for GDR shareholders. With Sareum I bought in at 0.4 and held for a decade and then sold a nice chunk at just over 8p (A x20+ gain and still holding quite a few in SAR even after the consolidation there). With Tek Capital I bought in at 6p and sold TEK at over 30p (& still holding quite a few there also). Both are at the forefront / cutting edge of their sectors. Synairgen was the same for me. I bought in at 29p, sold a chunk of SNG shares at over 200p. I still hold there too as I think there is potential, although less than there was. My due diligence always factors in significant speculative gains to be made, which is why another of my favourites is GDR. I can see the same rationale for investing that drew me to TEK, SAR, SNG, TXP, WEB etc. What I would say is that the facts are that the phrama sector is renowned for paying hundreds of millions for licencing and billions for takeovers. It is not unreasonable that £2, as you quite rightly state, is where you think this is heading. That would represent a x8 gain, which is well within our grasp. I actually think we will see more than £2 a share in due course if you are prepared to stay invested in GDR for a year+. Good luck, Brighty

For what it's worth, looking at how the pharma sector operates GDR has takeover or licencing written all over it now. Here's why:

* Takeovers and licencing deals are often now more about the potential of a new breakthrough science than just about sales in our particular sector. GSK announcing its takeover of Sierra being a classic example. It's about the future revenue / profits that GSK are buying in to. It's the same for many of the recent deals in our sector.

* Over the last twenty years large pharmas have also utilised takeover and licencing deals to buy in to new technologies spending billions and billions to replenish expiring patents and to stay ahead of their rivals.

* A couple of years ago McKinsey revealed that the share of revenues coming from innovations sourced outside of Big Pharma grew from approximately 25% in 2001 to about 50% currently, with large pharmas taking over those with candidates that have a high likelihood of success and using their scale to support advancement through late-stage development and then commercialisation.

Hope this helps as this is what I think could be the BIG opportunity for GDR and its shareholders. i.e. a mega licencing or takeover deal. GDR's recent announcement clearly now confirms that it has something that a major pharma is going to want in its portfolio. That could be worth a significant amount of money in our sector, especially as our mcap is only £25million approx currently.

Good luck, Brighty

Many on here are over looking the fact that in the pharma sector billions are paid in takeover deals for breakthrough science. For example:

* GSK last week announced the takeover of Sierra, a very small US based company, for US$1.9 billion in cash.

* 2 weeks ago Pfizer announced it will acquire ReViral for a total consideration of up to $525 million.

* Our latest news has put us in the shop window for a big pharma to take us over.

* GDR's current mcap of 25 Million is peanuts. GDR could easily be taken over for x 10. i.e. £225 million (280p approx a share).

Good luck, Brighty

I think you are right. News is due soon on several fronts and don't forget that GDR have not RNS'd news at 7am recently and have instead RNS'd news intraday at 10am on 29th March, 3.16pm on 21st March & 2pm on 18th March. I'm watching closely for an intraday RNS because when it comes it could be the tipping point that we have been waiting for which will see our share price rocket. Good luck, Brighty

Yes, another excellent milestone achieved. Key messages from the RNS from TEK today:

* Perrone Robotics Inc & Guident sign strategic alliance

* Accelerating the roll-out of land-based delivery drones

* The autonomous vehicle market is expected to reach $556 billion by 2026

* Guident and Perrone Robitics will be exhibiting at Comotion Miami on April 20th & 21st, 2022

* Potential Market: According to Allied Market Research, "The autonomous vehicle market is expected to reach $556 billion by 2026 with a CAGR of 39%.1 Contactless or "touch-free" delivery is in high demand due to the COVID 19 pandemic.

* Increased demand will accelerate the roll-out of land-based delivery drones for people, and a wide variety of products to improve mobility and reduce the costs of deliveries.

Don't forget that TEK owns 100% of the share capital of Guident. Happy days!

In a nutshell, TEK's portfolio of Guident, Lucyd, Salarius and Belluscura are all powering ahead creating huge potential shareholder value.

Good luck, Brighty

A similar deal here would value SAR at x 8 of our current 260p share price. I.e £20 a share or £1.4 billion approx. We operate in a multi billion sector. Bring it on! Good luck, Brighty

TEK's stake in BELL is now a whopping $30million approx. Our stake was valued at $10.8m on ipo day. That's an impressive 11 month gain. Imagine what $30million + cash will do to the TEK share price if Cliff and the team at TEK sell our stake in BELL. From the 6p days just 2 years ago this just gets better and better. Surely a 50p per share for TEK is not that far off and I'm still sticking with my £1 prediction for the end of 2022. Good luck, Brighty

Deirdre Michie, ceo of Offshore Energies UK (OEUK), is helping the BOIL cause with tv and press interviews yesterday telling ministers "to maximise the use of domestic resources". Good luck, Brighty

* Don't forget that we operate in a sector that thrives on takeovers. Just yesterday Pfizer announced it will acquire ReViral for a total consideration of up to $525 million, including upfront and development milestones AND as we know many takeovers in this sector are in the billions.

* With international headlines like the one just published, see below, which major pharma isn't going to want to miss out on GDR? A mega takeover or licencing deal looks a real possibility now:

"New Rapid genomic testing at Manchester University NHS Foundation Trust hospitals prevents at-risk neonates from potential lifelong hearing loss".

Good luck, Brighty